Trials / Completed
CompletedNCT01879163
Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults
A Phase I Randomised Trial to Evaluate the Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in Bacille Calmette-Guérin (BCG) Vaccinated Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- University of Oxford · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase I trial to evaluate the safety and immunogenicity of MVA85A-IMX313 vaccination compared to MVA85A vaccination, in BCG vaccinated adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MVA85A-IMX313 | Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313) |
| BIOLOGICAL | MVA85A | Intradermal injection of MVA85A (recombinant Modified Vaccinia virus Ankara expressing the M. tb antigen 85A) |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2013-06-17
- Last updated
- 2014-12-16
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01879163. Inclusion in this directory is not an endorsement.